GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Shanghai Pharmaceuticals Holding Co Ltd (SHSE:601607) » Definitions » Risk Assessment

Shanghai Pharmaceuticals Holding Co (SHSE:601607) Risk Assessment


View and export this data going back to 1994. Start your Free Trial

What is Shanghai Pharmaceuticals Holding Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shanghai Pharmaceuticals Holding Co is: Moderate Risk: Sensitive, better choose undervalued stock.


Competitive Comparison of Shanghai Pharmaceuticals Holding Co's Risk Assessment

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Pharmaceuticals Holding Co's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Risk Assessment falls into.



Shanghai Pharmaceuticals Holding Co  (SHSE:601607) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


Shanghai Pharmaceuticals Holding Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Shanghai Pharmaceuticals Holding Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Pharmaceuticals Holding Co (SHSE:601607) Business Description

Traded in Other Exchanges
Address
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding is a vertically integrated Chinese healthcare company that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the second-largest distributor by revenue and has a strong distribution presence in Eastern China.

Shanghai Pharmaceuticals Holding Co (SHSE:601607) Headlines

No Headlines